000			03833nam a22007337a 4500
008			200826s20202020 xxu||||| |||| 00| 0 eng d
022			_a0190-9622
024			_a10.1016/j.jaad.2020.06.051 [doi]
024			_aPMC7303642 [pmc]
024			_aS0190-9622(20)31149-X [pii]
040			_aOvid MEDLINE(R)
099			_a32569797
245			_aNavigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. [Review]
251			_aJournal of the American Academy of Dermatology. 83(4):1150-1159, 2020 Oct.
252			_aJ Am Acad Dermatol. 83(4):1150-1159, 2020 Oct.
252			_zJ Am Acad Dermatol. 2020 Jun 19
253			_aJournal of the American Academy of Dermatology
260			_c2020
260			_fFY2021
265			_saheadofprint
265			_sppublish
266			_d2020-08-26
268			_aJournal of the American Academy of Dermatology. 2020 Jun 19
269			_fFY2020
520			_aDermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the SARS-CoV-2 pandemic. Though the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in COVID-19 are scarce. This article reviews and offers guidance based upon currently available safety data, and the most recent COVID-19 outcome data, in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasize a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic. Copyright (c) 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
546			_aEnglish
650			_a*Coronavirus Infections/pc [Prevention & Control]
650			_a*Dermatology/st [Standards]
650			_a*Immunosuppression/st [Standards]
650			_a*Pandemics/pc [Prevention & Control]
650			_a*Pneumonia, Viral/pc [Prevention & Control]
650			_a*Practice Guidelines as Topic
650			_a*Skin Diseases/th [Therapy]
650			_aAdvisory Committees/st [Standards]
650			_aBetacoronavirus/im [Immunology]
650			_aBetacoronavirus/py [Pathogenicity]
650			_aClinical Decision-Making
650			_aCoronavirus Infections/ep [Epidemiology]
650			_aCoronavirus Infections/im [Immunology]
650			_aCoronavirus Infections/vi [Virology]
650			_aDecision Making, Shared
650			_aDermatologists/st [Standards]
650			_aDermatology/mt [Methods]
650			_aDisease Susceptibility/im [Immunology]
650			_aHospitalists/st [Standards]
650			_aHumans
650			_aImmunosuppression/ae [Adverse Effects]
650			_aImmunosuppression/mt [Methods]
650			_aInterdisciplinary Communication
650			_aPneumonia, Viral/ep [Epidemiology]
650			_aPneumonia, Viral/im [Immunology]
650			_aPneumonia, Viral/vi [Virology]
650			_aSkin Diseases/im [Immunology]
650			_aSocieties, Medical/st [Standards]
650			_aSymptom Flare Up
651			_aMedStar Washington Hospital Center
656			_aDermatology
657			_aJournal Article
657			_aReview
700			_aPasieka, Helena B
790			_aAnadkat MJ, Chen ST, Fox LP, Harp J, Merola JF, Micheletti RG, Nambudiri VE, Niaki OZ, Pasieka HB, Rosenbach M, Shinohara MM
856			_uhttps://dx.doi.org/10.1016/j.jaad.2020.06.051 _zhttps://dx.doi.org/10.1016/j.jaad.2020.06.051
942			_cART _dArticle
999			_c5276 _d5276